Navigation Links
GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
Date:8/25/2009

in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... somehow survived where other traditional marketing tools and old ... must face harsher realities once again, all to ensure ... Web sites are simply doomed. While billions of Web ... clash into the billions of surfing customers and simply ...
... Ted Kanavas, R-Brookfield, called on the Legislature and the ... Development Fund. , ,The fund would use existing information ... Administration and segregate a portion of the funds for ... would not flow into this fund. , ,This fund ...
... Corporation and First Data Corporation jointly ... provides for the purchase of substantially all of the ... approximately $610 million in cash. As the majority shareholder ... million and NYCE will become a Metavante subsidiary. , ...
Cached Biology Technology:The mysteries and the future of Web sites 2The mysteries and the future of Web sites 3The mysteries and the future of Web sites 4Metavante and First Data to buy PIN-debit company NYCE 2
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... President and Scientific Director and Director of the Hematopoiesis ... cliniques de Montral (IRCM), and his team was recently ... the American Society of Hematology. The researchers found that ... cells, which could lead to a better treatment for ...
... University of California, Riverside Bourns College of Engineering ... recently awarded a five-year, $6.25 million grant to ... for soldiers increasingly reliant on electronic devices. ... department of environmental and chemical engineering, and researchers ...
... Amid growing concern that synthetic life sciences pose biosecurity ... DNA sequence trade. Research published today in the ... looks at the necessity of a global regulator for ... Synthetic life sciences are making breakthroughs at a ...
Cached Biology News:A scientific breakthrough could be the first step in a better treatment for leukemia patients 2Research aims to lighten load carried by soldiers 2Technology to screen for synbio abuses lags 2Technology to screen for synbio abuses lags 3